GLPwatch
Papers (9189)
Page 82 of 154, ranked by citation count.
- A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease.
- The glucagon-like peptide 1 receptor agonist Exendin-4 induces tenogenesis in human mesenchymal stem cells.
- Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
- Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.
- pH-temperature Responsive Hydrogel-Mediated Delivery of Exendin-4 Encapsulated Chitosan Nanospheres for Sustained Therapeutic Efficacy in Type 2 Diabetes Mellitus.
- Glucagon-Like Peptide-1 Agonists: A Practical Overview for Plastic and Reconstructive Surgeons.
- Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?
- Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.
- Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study.
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
- Safety and efficacy of liraglutide treatment in Japanese type 2 diabetes patients after acute myocardial infarction: A non-randomized interventional pilot trial.
- Semaglutide, suicidal ideation and behaviour: A resting state functional magnetic resonance imaging perspective.
- Effects of selenium and exendin-4 on glucagon-like peptide-1 receptor, IRS-1, and Raf-1 in the liver of diabetic rats.
- The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France.
- In vitro performance of composition-equivalent PLGA microspheres encapsulating exenatide acetate by solvent evaporation.
- Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report.
- Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
- Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
- Pioneering oral peptide therapy for patients with type 2 diabetes.
- PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
- The acute anorexic effect of liraglutide, a GLP-1 receptor agonist, does not require functional leptin receptor, serotonin, and hypothalamic POMC and CART activities in mice.
- Design, evaluation, and in vitro-in vivo correlation of self-nanoemulsifying drug delivery systems to improve the oral absorption of exenatide.
- Bullous Pemphigoid Triggered by Liraglutide.
- Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.
- Exendin-4 decreases ghrelin levels through mTOR signaling.
- Efficacy and Cardiovascular Safety of GLP-1 Receptor Analogues.
- Determination of the Plasma Protein Binding of Liraglutide Using the EScalate<sup>*</sup> Equilibrium Shift Assay.
- Glucagon-like peptide-1 receptors agonists (GLP1 RA).
- Tackling suboptimal clinical response after metabolic bariatric surgery: Impact of tirzepatide on weight loss and body composition.
- Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.
- Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents.
- Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article.
- Semaglutide in renal ischemia-reperfusion injury in mice.
- Glucagon-like peptide-1 receptor activation stimulates PKA-mediated phosphorylation of Raptor and this contributes to the weight loss effect of liraglutide.
- Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?
- Risk and Benefit Profile of Dulaglutide in Established Therapeutic Indication.
- Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
- In vitro comparison of various antioxidants and flavonoids from Rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death.
- A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease.
- Semaglutide in Psychiatry-Opportunities and Challenges.
- Anterior ischemic optic neuropathy in patients treated with semaglutide: report of four cases with a possible association.
- Semaglutide mitigates testicular damage in diabetes by inhibiting ferroptosis.
- The Impact of Glucagon-Like Peptide-1 Receptor Agonist on the Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis and Systematic Review.
- Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology.
- The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark.
- Beta Cell Imaging-From Pre-Clinical Validation to First in Man Testing.
- Dimerization/oligomerization of the extracellular domain of the GLP-1 receptor and the negative cooperativity in its ligand binding revealed by the improved NanoBiT.
- Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder.
- The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- GLP-1RA-induced delays in gastrointestinal motility: Predicted effects on coadministered drug absorption by PBPK analysis.
- Semaglutide outperforms insulin in restoring neutrophil function against implant-related infection in diabetic and obese mice: experimental research.
- Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
- Liraglutide reduces hyperglycemia-induced cardiomyocyte death through activating glucagon-like peptide 1 receptor and targeting AMPK pathway.
- Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis.
- Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes.
- Tirzepatide-Induced Injection Site Reaction.
- Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
- The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.